PureTech Health (PRTC)
| Bid | 13.03 |
| Market Cap | 424.17M |
| Revenue (ttm) | 466.57K |
| Net Income (ttm) | -82.14M |
| EPS (ttm) | 2.1 |
| PE Ratio (ttm) | 8.41 |
| Forward PE | -2.59 |
| Analyst | Buy |
| Ask | 18.5 |
| Volume | 2,789 |
| Avg. Volume (20D) | 4,862 |
| Open | 17.69 |
| Previous Close | 17.26 |
| Day's Range | 17.52 - 17.82 |
| 52-Week Range | 13.30 - 32.98 |
| Beta | 1.25 |
About PRTC
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platfo...
Analyst Forecast
According to 1 analyst ratings, the average rating for PRTC stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 154.81% from the latest price.
Stock Forecasts
1 week ago · businesswire.com
PureTech Health: Notice of ResultsBOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
3 weeks ago · businesswire.com
PureTech Health plc Statement Regarding Press SpeculationBOSTON--(BUSINESS WIRE)--Statement regarding press speculation.
